Skip to main content

2021 to 2023 Saw Considerable Increase in Semaglutide Fills

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 5, 2024.

via HealthDay

MONDAY, Aug. 5, 2024 -- From 2021 through 2023, there was a considerable increase in the number of semaglutide fills, according to a research letter published online Aug. 2 in JAMA Health Forum.

Christopher Scannell, M.D., Ph.D., from the University of Southern California in Los Angeles, and colleagues analyzed trends in prescriptions dispensed at retail pharmacies for semaglutide between January 2021 and December 2023. Monthly fills were calculated for semaglutide by drug brand (Ozempic, Wegovy, and Rybelsus) and payment method.

The researchers observed a 442 percent increase in the number of semaglutide fills between January 2021 and December 2023; Ozempic accounted for more than 70 percent of these fills. Increases were seen for all three drug brands, with variation in the extent and timing of these increases. Ozempic increased 392 percent between January 2021 and December 2023, peaking in August 2023 before reaching a plateau; notable increases in Wegovy fills started in January 2023, peaked in May 2023, then plateaued, with an increase of more than 1,361 percent seen between July 2021 and December 2023. For all three drug brands, increases in monthly semaglutide fills were seen across all payment methods between 2021 and 2023, with most fills accounted for by prescriptions paid through commercial insurance.

"The number of prescriptions filled for semaglutide has increased substantially, reaching 2.6 million prescriptions filled at retail pharmacies by December 2023," the authors write. "Future research should examine how changes in Medicare Part D and Medicaid coverage restrictions influence disparities in access to these essential medications."

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Rebound Weight Gain Common After Discontinuing Antiobesity Medications

FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...

Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes

FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...

GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D

THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.